References
1. van Haren, F.M.P., et al., Nebulised heparin as a treatment for
COVID-19: scientific rationale and a call for randomised evidence. Crit
Care, 2020. 24 (1): p. 454.
2. Dixon, B., et al., Nebulized heparin reduces levels of
pulmonary coagulation activation in acute lung injury. Crit Care, 2010.14 (5): p. 445.
3. Dixon, B., et al., Nebulized heparin is associated with fewer
days of mechanical ventilation in critically ill patients: a randomized
controlled trial. Crit Care, 2010. 14 (5): p. R180.
4. Dixon, B., et al., A trial of nebulised heparin to limit lung
injury following cardiac surgery. Anaesth Intensive Care, 2016.44 (1): p. 28-33.
5. Dixon, B., et al., Nebulised heparin for patients with or at
risk of acute respiratory distress syndrome: a multicentre, randomised,
double-blind, placebo-controlled phase 3 trial. Lancet Respir Med,
2021. 9 (4): p. 360-372.
6. Ciceri, F., et al., Microvascular COVID-19 lung vessels
obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute
respiratory distress syndrome working hypothesis. Crit Care Resusc,
2020. 22 (2): p. 95-97.
7. Shute, J.K., et al., Inhaled nebulised unfractionated heparin
improves lung function in moderate to very severe COPD: A pilot study.Pulm Pharmacol Ther, 2018. 48 : p. 88-96.
8. Clausen, T.M., et al., SARS-CoV-2 Infection Depends on Cellular
Heparan Sulfate and ACE2. Cell, 2020. 183 (4): p. 1043-1057
e15.
9. Tree, J.A., et al., Unfractionated heparin inhibits live wild
type SARS-CoV-2 cell infectivity at therapeutically relevant
concentrations. Br J Pharmacol, 2021. 178 (3): p. 626-635.
10. Mulloy, B., et al., Pharmacology of Heparin and Related
Drugs. Pharmacol Rev, 2016. 68 (1): p. 76-141.
11. Tandon, R., et al., Effective Inhibition of SARS-CoV-2 Entry
by Heparin and Enoxaparin Derivatives. J Virol, 2021. 95 (3).
12. Thachil, J., Lessons learnt from COVID-19 coagulopathy.EJHaem, 2021.
13. van Haren, F.M.P., et al., INHALEd nebulised unfractionated
HEParin for the treatment of hospitalised patients with COVID-19
(INHALE-HEP): Protocol and statistical analysis plan for an
investigator-initiated international metatrial of randomised studies.Br J Clin Pharmacol, 2021. 87 (8): p. 3075-3091.
14. Dahlberg, S.E., et al., Clinical Versus Statistical
Significance in Studies of Thoracic Malignancies. J Thorac Oncol, 2020.15 (9): p. 1406-1408.
15. Haren, F.M.P.v., Inhaled nebulised unfractionated heparin for
the treatment of hospitalised patients with COVID-19: A multicentre case
series of 98 patients. British Journal Clinical Pharmacology, 2022.
16. Takayama, W., A. Endo, and Y. Otomo, Anticoagulation therapy
using unfractionated heparin at a therapeutic dose for coronavirus
disease 2019 patients with severe pneumonia: a retrospective historical
control study. Acute Med Surg, 2021. 8 (1): p. e679.